Table 1.
The 10 most cited papers in melanoma immunotherapy between 2010 and 2022a a .
| Rank | Title | Corresponding Author |
Year | Total citations | Average citations per year (rank) |
|---|---|---|---|---|---|
| 1 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Hodi, FS | 2010 | 9824 | 818.7 (1) |
| 2 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Hodi, FS | 2015 | 4953 | 707.6 (2) |
| 3 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation | Robert, C | 2015 | 3549 | 507 (3) |
| 4 | Pembrolizumab versus Ipilimumab in Advanced Melanoma | Robert, C | 2015 | 3506 | 500.9 (4) |
| 5 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma | Wolchok, JD | 2011 | 3113 | 283 (10) |
| 6 | Nivolumab plus Ipilimumab in Advanced Melanoma | Wolchok, JD | 2013 | 2940 | 326.7 (9) |
| 7 | Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma | Chan, TA | 2014 | 2614 | 326.8 (8) |
| 8 | Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma | Ribas, A | 2013 | 2496 | 277.3 (11) |
| 9 | Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma | Hodi, FS | 2015 | 1856 | 265.1 (14) |
| 10 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Wolchok, JD | 2017 | 1840 | 368 (6) |
a
These ten papers were all published on N. Engl. J. Med.